Larisa G. Goryacheva

Larisa G. Goryacheva

Auto-generated profile, based on publicly available information

Larisa G. Goryacheva

Saint Petersburg State Pediatric Medical University; Pediatric Research and Clinical Center for Infectious Diseases

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Infectious diseases: News, Opinions, Training
Verified
Journal Article
Closed access
NVN.D. Ventslovayte
N.D. Ventslovayte
LGL.G. Goriacheva
L.G. Goriacheva
PRPetersburg State Pediatric Medical University of the Ministry of Health of Russia
Petersburg State Pediatric Medical University of the Ministry of Health of Russia
VGV.A. Greshnyakova
V.A. Greshnyakova
NEN.A. Efremova
N.A. Efremova
ISI.V. Shilova
I.V. Shilova
Опыт терапии хронического вирусного гепатита С у детей старше 12 лет комбинированным препаратом прямого противовирусного действия, содержащим

10 December 2021 in CHILDREN INFECTIONS
Verified
Journal Article
Open access
PDF file
LGL. G. Goriacheva
L. G. Goriacheva
NVN. D. Ventslovayte
N. D. Ventslovayte
VGV. A. Greshnyakova
V. A. Greshnyakova
The problem of viral hepatitis (VH) today is an acute problem for the world healthcare system. Along with the COVID-19 pandemic, the VH pandemic claims up to 1.5 million lives annually. Since 2016, the Russian Federation has launched a WHO program aimed at combating VH. One of the first steps on the path of global elimination is getting rid of the virus in the small groups, among which micro-elimination in the child population is one of the promising areas.This review is devoted to the current state of the problem of VH in children in the Russian Federation today. The success of vaccine prevention (against viral hepatitis A and B) made it possible to achieve results in the form of a significant decrease in the incidence of children, minimizing the risk of perinatal infection. However, in recent years, there has been a progressive decline in vaccination coverage. This is mainly due to the growing popularity of anti-vaccination lobbies, a decrease in the awareness of patients and health workers about the need for timely vaccination, as well as the introduction of restrictive measures to prevent a new coronavirus infection. The emergence of mutant, "vaccine-eluting" strains, which are also resistant to available antiviral drugs, is another serious problem on the way to eliminating viral HBV. In the field of treating children with HBV, the possibilities are extremely limited, only 2 drugs are available, one of which (tenofovir alafenamide) is available only from the age of 12. Registration of direct antiviral drugs for the treatment of adolescents with chronic hepatitis C has made it possible to bring closer the goal of microelimination of the virus in children. However, the high cost of drugs poses a challenge for the state to introduce long-term benefit programs to ensure the availability of treatment. In addition, at the moment, the treatment of young children in our country remains a prospect for the future.Thus, despite significant advances in the strategy for the elimination of viral hepatitis, a number of problems remain relevant and present significant difficulties in achieving the global goal.

1 January 2022 in Infectious diseases: News, Opinions, Training
Verified
Journal Article
Closed access
NVN.D. Ventslovayte
N.D. Ventslovayte
LGL.G. Goriacheva
L.G. Goriacheva
NGN.V. Gonchar
N.V. Gonchar
VGV.A. Greshnyakova
V.A. Greshnyakova
NEN.A. Efremova
N.A. Efremova
Патогенетическая связь между состоянием микробиоты кишечника и заболеваниями печени

23 May 2025 in Pediatric pharmacology
Verified
Journal Article
Open access
PDF file
ABAlexander A. Baranov
Alexander A. Baranov
GVGalina V. Volynets
Galina V. Volynets
NVNikolay N. Vlasov
Nikolay N. Vlasov
LGLarisa G. Goryacheva
Larisa G. Goryacheva
MGMargarita M. Gurova
Margarita M. Gurova
AHAnatoly I. Havkin
Anatoly I. Havkin
The authors present modern epidemiological data and features of the etiopathogenesis of metabolically associated fatty liver disease in children (non-alcoholic fatty liver disease), and provide clinical characteristics of various variants of this nosology. Information is provided on laboratory, instrumental and morphological signs of metabolically associated fatty liver disease in children, as well as on methods of prevention, treatment and rehabilitation in accordance with developed clinical guidelines.

30 June 2020 in CHILDREN INFECTIONS
Verified
Journal Article
Open access
PDF file
NVN. D. Ventslovayte
N. D. Ventslovayte
NEN. A. Efremova
N. A. Efremova
LGL. G. Goriacheva
L. G. Goriacheva
OGO. A. Gerasimova
O. A. Gerasimova
Liver transplantation today is the only radical method of treatment decompensating fulminant and chronic liver failure. The operation technic and patient care improvement made it possible to achieve a high survival rate. Transplantation has become an available and safe method for children, including patients weighing less than 10 kg. However, at the moment there are a number of unsolved problems. Postoperative complications can significantly affect the results of transplantation. This article provides a Russian and foreign literature overview, reflecting the achievements in the field of liver, identifying current problems and solutions.

21 March 2022 in CHILDREN INFECTIONS
Verified
Journal Article
Open access
PDF file
VGV. A. Greshnyakova
V. A. Greshnyakova
LGL. G. Goriacheva
L. G. Goriacheva
ANA. O. Nikiforova
A. O. Nikiforova
Инфекционный мононуклеоз: нетипичная манифестация